Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
- Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
- Japan Govt to Set Biosimilar Target by March 2023: Honebuto Draft
June 6, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- LDP Pharma Study Group Prods Rethink of Annual Re-Pricing, but Health Minister Sounds Negative
June 3, 2022
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
June 3, 2022
- Working Group Urges Govt to Discuss Use of Anonymized Medical Data for Regulatory Purposes
June 2, 2022
- Panel OKs Orphan Designation for Pfizer’s Hemophilia Gene Therapy
June 2, 2022
- Honebuto Draft Fails to Clear LDP, Renewed Discussions Set for June 3
June 2, 2022
- Govt’s Draft Grand Design for New Capitalism Vows to Spur Biotechnology Innovation
June 1, 2022
- Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
- ViiV’s Vocabria, Janssen’s Rekambys for HIV to Join NHI Price List on June 8
June 1, 2022
- Post-Launch Safety Steps to Be More Important with Emergency Approval: Official
May 31, 2022
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
- Lawmakers’ League on Vaccines Urges Enhanced R&D System for Homegrown Jabs
May 30, 2022
- Orphan Tag Granted for Eisai’s ALS Drug, 3 Other APIs
May 30, 2022
- Deregulation Panel Urges Better Data Infrastructure, DCT Promotion to Boost Drug Discovery in Japan
May 30, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…